Zomedica Q1 revenue record $8.8M, up 35% YoY; net loss narrows to $4.5M

Zomedica Corp.

2026-Q1 EPS reported $0.00 revenue$8,799,000

Record Q1 revenue $8.8M, up 35% from $6.5M in Q1 2025; 21st straight quarter of YoY growth.
Diagnostics segment revenue $1.0M, +73% YoY; Therapeutic Devices $5.8M flat; Development Services $2.0M.
Net loss $4.5M vs $63.8M in prior year which included $55.8M impairment; Adjusted EBITDA loss improved 58% to $2.4M.
Cash burn reduced 15% to $5.7M; liquidity $47.5M as of March 31, 2026.
Launched TRUVIEW AI telepathology platform and announced collaboration with Boehringer Ingelheim for equine PPID testing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zomedica Corp. reported the first quarter ended March 31, 2026 results: revenue $8.8 million.

Period: the first quarter ended March 31, 2026
Revenue: $8.8 million
Result: reported results

Exact text from the filing

Zomedica Announces Record First Quarter Revenue of $8.8 Million

View on SEC.gov

Browse all earnings releases →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-26-004419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.